| Diseases | Sources | Cargos/pathway | Doses | Mode of administration | Species | Results | Ref |
| SCI | BMMSCs | — | 100 μg | Single dose, IV | Rats | Angiogenesis, anti-apoptosis and anti-inflammation | [88] | SCI | BMMSCs | Wnt/β-catenin pathway | 200 μg | Ten doses (three days apart), | Rats | Antiapoptosis | [89] | SCI | BMMSCs | NF-κB pathway | 40 μg | Single dose, IV | Rats | BSCB integrity | [91] | SCI | BMMSCs | NF-κB pathway | 200 μg/40 μg | Single dose, IV | Rats | Anti-inflammation | [92, 93] | SCI | hucMSCs | — | 20/200 μg | Single dose, IV | Mice | Anti-inflammation | [95] | SCI | BMMSCs | miR-216a-5p | 200 μg | Single dose, IV | Mice | Anti-inflammation | [97] | SCI | BMMSCs | miR-133b | 100 μg | Single dose, IV | Rats | Neurogenesis | [100] | SCI | BMMSCs | miR-126 | 100 μg | Seven doses (once daily), IV | Rats | Neurogenesis, angiogenesis and anti-apoptosis | [101]. | SCI | BMMSCs | PTEN-siRNA | particles | Five doses (once daily), IN | Rats | Neurogenesis and angiogenesis | [102] | TBI | BMMSCs | — | 30 μg | Single dose, retro-orbital injection | Mice | Anti-inflammation | [104] | TBI | AMSCs | LncMALAT1 | 100 μg | Single dose, IV | Rats | Neurogenesis, antiapoptosis and anti-inflammation | [105] | TBI | BMMSCs | miR-216a-5p | 100 μg | Single dose, IV | Rats | Neurogenesis and anti-inflammation | [109] | Stroke | UMSCs | miR-26a | particles | Single dose, IV | Rats | Neurogenesis | [111] | Stroke | AMSCs | miR-126 | _ | Single dose, IV | Rats | Neurogenesis, angiogenesis and anti-inflammation | [113]. | Stroke | BMMSCs | miR-138-5p | — | — | Mice | Anti-inflammation | [114] | Stroke | BMMSCs | miR-133b | 100 μg | Single dose, intra-arterial injection | Rats | Neurogenesis | [115, 116] | Stroke | BMMSCs | miR-17-92 cluster | 100 μg | Single dose, IV | Rats | Neurogenesis | [117] | Stroke | hucMSCs | CCR2 | 100 μg | Single dose, IV | Rats | Anti-inflammation | [120] | AD | hucMSCs | miR-223 | 2 μg | — | Cell model | Antiapoptosis | [128] | AD | hucMSCs | Neprilysin, IDE, HSP70, HSP90 | 12 μg/day | Fourteen consecutive days of Alzet minipump injection | Mice | Aβ peptides clearance and anti-inflammation | [129] | AD | MSCs | miR-21 | 150 μg | Five doses (two weeks apart), IV | Mice | Anti-inflammation | [130] | AD | BMMSCs | — | particles | Four doses (monthly), IV | Mice | Aβ peptides clearance and anti-inflammation | [131] | PD | DPMSCs | — | — | — | Cell model | Antiapoptosis | [134] |
|
|